The role of Daflon 500 mg in the treatment of symptomatic patients with varicose veins

Phlebolymphology

Volumn , Issue 47, 2004, Pages 320-323

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CELL ADHESION MOLECULE; DAFLON; FLAVONOID; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; VASCULAR CELL ADHESION MOLECULE 1;

CELL INFILTRATION; CHRONIC VEIN INSUFFICIENCY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; LEG CRAMP; LEG EDEMA; LEG PAIN; LEG SWELLING; LEG ULCER; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION INHIBITION; NONHUMAN; OUTCOMES RESEARCH; PHYSICAL DISABILITY; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SYMPTOM; THROMBOPHLEBITIS; ULCER HEALING; VARICOSIS; VASCULAR ENDOTHELIUM; VEIN BLOOD FLOW; VEIN VALVE;

EID: 10644273544     PISSN: 12860107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Aravind B, Davies AH. Editorial. Phlebology. 2004;19:55-56.
2. Porter JM, Moneta GL. International Consensus Committee on chronic venous disease. Reporting standards in venous disease: an update. J Vasc Surg. 1995;21:635-645.
3. International Task Force. The management of chronic venous disorders of the leg: an evidence-based report of an international task force. Phlebology. 1999;14(Suppl. 1):23-34.
4. Schultz-Ehrenburg U, Weindorf N, Matthes-U, et al. Epidemiological study on the pathogenesis of varicose veins (Bochum I-III) [in French]. Phlébologie. 1992;45:497-500.
5. Schultz-Ehrenburg U, Reich S, Robak-Pawelczyk B, Altmeyer P, Stücker M. Prospective epidemiological study of developing varicose veins over a period of two decades (Bochum I-IV). Abstract presented at the 2003 UIP World Chapter Meeting. August 27-31, 2003, in San Diego, California, USA.
6. Widmer LK, Holz D, Morselli B, Zbinden O, et al. Progression of varicose veins in 11 years. Observations on 1441 working persons of the Basle Study. Unpublished paper. Basle: Angiology Division of University Dpt of Medicine, 1992. Results summarized in: International Task Force: the management of chronic venous disorders of the leg. Phlebology. 1999;14(Suppl. 1):23-34.
7. Vanhoutte PM, Corcaud S, de Montrion C. Venous disease: from pathophysiology to quality of life. Angiology. 1997;48:559-567.
8. Wali MA, Eid RA. Intimal changes in varicose veins: an ultrastructural study. J Smooth Muscle Res. 2002;38:63-74.
9. Carpentier PH, Cornu-Thénard A, Uhl JF, Partsch H, Antignani PL. Appraisal of the information content of the C classes of CEAP clinical classification of chronic venous disorders: a multicenter evaluation of 872 patients. J Vasc Surg. 2003;37:827-833.
10. Kaplan RM, Criqui MH, Denenberg JO, Bergan J, Fronek A. Quality of life in patients with chronic venous disease: San Diego population study. J Vasc Surg. 2003;37:1047-1053.
11. Perrin M, Arnould B, Regnault A, Launois R. Relationship between symptoms, signs, reflux, and quality of life in patients with chronic venous disease: a multicentre study. Oral presentation at the 16th Annual Meeting of the American Venous Forum (AVF), Orlando, USA, February 26-29, 2004.
12. Kurz X, Lamping DL, Baccaglini U, Zuccarelli F, Spreafico G, Abenhain L, and the VEINES Study Group. Do varicose veins affect quality of life? Results of an international population-based study. J Vasc Surg. 2001;34:641-648.
13. Bergan JJ, Schmid Schönbein G, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology. 2001;Suppl. 1:S43-S47.
14. Friesenecker B, Tsai AG, Intaglietta M. Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Int J Microcirc Clin Exp. 1995;15(Suppl. 1):17-21.
15. Korthuis RJ, Gute DC. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc Res. 1999;36(Suppl. 1):15-23.
16. Shoab SS, Porter JB, Scurr JH, et al. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease-a pilot study. J Vasc Surg. 2000;31:456-461.
17. Ono T, Bergan JJ, Schmid-Schönbein GN, Takase S. Monocyte infiltration into venous valves. J Vasc Surg. 1998;27:158-166.
18. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schönbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg. In press.
19. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002;53:245-256.
20. Guillot B, Guilhou JJ, de Champvallins M, et al. A long term treatment with a venotropic drug: results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol. 1989;8 (Suppl. 4):67-71.
21. Blume J, Langenbahn H, de Champvallins M. Quantification of edema using the volometer technique; therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology. 1992;7(Suppl. 2):37-40.
22. Arnould B, Regnault A, Perrin M. Change in the quality of life in patients with chronic venous disease: results of a 6-month study using Daflon 500 mg. European Venous Forum abstracts, June 25-27, 2004. Phlebology. 2004;19:2.
23. Ramelet AA, Coleridge Smith PD, Gloviczki P. Factors affecting venous leg ulcer healing. Abstracts of the 21st World Congress of the International Union of Angiology. Int Angiol. 2004;21 (Suppl. 1):158.